Abcely
Develops oral sIgA immunotherapies for mucosal cancers and other mucosal diseases
Highlights
- Young companyFounded 2022
- New on EvolcAdded 2026-11-10
About Abcely
ABCELY is developing an oral immunotherapy platform based on secretory IgA (sIgA) to create drug candidates for mucosal diseases. Its pipeline includes candidates for colorectal cancer, endometriosis and inflammatory bowel diseases.
The company develops candidates from target identification through early preclinical validation and pursues strategic partnerships and out-licensing. ABCELY was founded in 2022 and is headquartered in Nantes, France; its team includes scientific, pharmaceutical development, regulatory and finance leaders.
Product: An oral sIgA immunotherapy platform and drug candidates for mucosal diseases.
Jobs at Abcely
Leadership
- Jean-Marc Herbert · Founder and CEOSource: company website
- François Desmarest · Chief Financial OfficerSource: company website
- Olivier Favre-Bulle · Chief Technology OfficerSource: company website
More biotech & pharma companies
Abivax
Develops obefazimod and other therapeutics for patients with chronic inflammatory diseasesABL
Molecular diagnostic assays, sequencing analysis software and specimen collection kits for clinical labs, researchers and hospitalsAbleads
Develops personalized therapeutic antibodies for cancer patients with tumors that have low mutation ratesNew on EvolcAboleris Pharma
Develops immune-tolerance therapies for patients with autoimmune diseases and organ transplant rejectionNew on EvolcActicor Biotech
Clinical-stage biopharma developing glenzocimab, an antithrombotic antibody fragment for acute ischemic stroke patientsNew on EvolcActiv-H
Superacid flow chemistry R&D services for pharmaceutical and biotech drug discovery teamsYoung companyNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content management
- ElementorHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Forms
- Google reCAPTCHAHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- ApacheHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.